Allen K B, Dowling R D, Fudge T L, Schoettle G P, Selinger S L, Gangahar D M, Angell W W, Petracek M R, Shaar C J, O'Neill W W
Department of Cardiothoracic Surgery, St. Vincent Hospital and Indiana Heart Institute, Indianapolis, USA.
N Engl J Med. 1999 Sep 30;341(14):1029-36. doi: 10.1056/NEJM199909303411403.
Transmyocardial revascularization involves the creation of channels in the myocardium with a laser to relieve angina. We compared the safety and efficacy of transmyocardial revascularization performed with a holmium laser with those of medical therapy in patients with refractory class IV angina (according to the criteria of the Canadian Cardiovascular Society).
In a prospective study conducted between March 1996 and July 1998 at 18 centers, 275 patients with medically refractory class IV angina and coronary disease that could not be treated with percutaneous or surgical revascularization were randomly assigned to receive transmyocardial revascularization followed by continued medical therapy (132 patients) or medical therapy alone (143 patients).
After one year of follow-up, 76 percent of the patients who had undergone transmyocardial revascularization had improvement in angina (a reduction of two or more classes), as compared with 32 percent of the patients who received medical therapy alone (P<0.001). Kaplan-Meier survival estimates at one year (based on an intention-to-treat analysis) were similar for the patients assigned to undergo transmyocardial revascularization and those assigned to receive medical therapy alone (84 percent and 89 percent, respectively; P=0.23). At one year, the patients in the transmyocardial-revascularization group had a significantly higher rate of survival free of cardiac events (54 percent, vs. 31 percent in the medical-therapy group; P<0.001), a significantly higher rate of freedom from treatment failure (73 percent vs. 47 percent, P<0.001), and a significantly higher rate of freedom from cardiac-related rehospitalization (61 percent vs. 33 percent, P<0.001). Exercise tolerance and quality-of-life scores were also significantly higher in the transmyocardial-revascularization group than in the medical-therapy group (exercise tolerance, 5.0 MET [metabolic equivalent] vs. 3.9 MET; P=0.05); quality-of-life score, 21 vs. 12; P=0.003). However, there were no differences in myocardial perfusion between the two groups, as assessed by thallium scanning.
Patients with refractory angina who underwent transmyocardial revascularization and received continued medical therapy, as compared with similar patients who received medical therapy alone, had a significantly better outcome with respect to improvement in angina, survival free of cardiac events, freedom from treatment failure, and freedom from cardiac-related rehospitalization.
心肌激光血运重建术是利用激光在心肌上制造通道以缓解心绞痛。我们比较了钬激光心肌激光血运重建术与药物治疗对难治性Ⅳ级心绞痛患者(根据加拿大心血管学会的标准)的安全性和疗效。
在1996年3月至1998年7月期间于18个中心进行的一项前瞻性研究中,275例药物治疗无效的Ⅳ级心绞痛且无法接受经皮或外科血运重建治疗的冠心病患者被随机分配接受心肌激光血运重建术并继续药物治疗(132例患者)或仅接受药物治疗(143例患者)。
随访一年后,接受心肌激光血运重建术的患者中有76%的人心绞痛症状改善(降低两级或更多级),而仅接受药物治疗的患者中这一比例为32%(P<0.001)。根据意向性分析,接受心肌激光血运重建术的患者与仅接受药物治疗的患者一年时的Kaplan-Meier生存估计相似(分别为84%和89%;P=0.23)。一年时,心肌激光血运重建术组患者无心脏事件生存的比例显著更高(54%,而药物治疗组为31%;P<0.001),无治疗失败的比例显著更高(73%对47%,P<0.001),无心脏相关再住院的比例显著更高(61%对33%,P<0.001)。心肌激光血运重建术组的运动耐量和生活质量评分也显著高于药物治疗组(运动耐量,5.0代谢当量对3.9代谢当量;P=0.05);生活质量评分,21对12;P=0.003)。然而,通过铊扫描评估,两组之间的心肌灌注没有差异。
与仅接受药物治疗的类似患者相比,接受心肌激光血运重建术并继续药物治疗的难治性心绞痛患者在心绞痛改善、无心脏事件生存、无治疗失败以及无心脏相关再住院方面的结局显著更好。